HIV vaccine, Vaccination, HIV/AIDS, Immune system, Infectious disease, AIDS

Gilead Sciences and Gritstone Announce Collaboration Utilizing Gritstone’s Vaccine Platform Technology for HIV Cure

On Feb 1, 2021
@GileadSciences shared
Today, we announced our collaboration with Gritstone to research and develop a vaccine-based immunotherapy as part of Gilead’s efforts to find a potentially curative treatment for HIV infection: https://t.co/yaCEyiWXjI https://t.co/OwtxHnuwLS
Open

Gilead Sciences and Gritstone Announce Collaboration Utilizing Gritstone’s Vaccine Platform Technology for HIV Cure

www.gilead.com
On Feb 1, 2021
@GileadSciences shared
Today, we announced our collaboration with Gritstone to research and develop a vaccine-based immunotherapy as part of Gilead’s efforts to find a potentially curative treatment for HIV infection: https://t.co/yaCEyiWXjI https://t.co/OwtxHnuwLS
Open

Gilead Sciences and Gritstone Announce Collaboration Utilizing Gritstone’s Vaccine Platform Technology for HIV Cure

Gilead Sciences and Gritstone Announce Collaboration Utilizing Gritstone’s Vaccine Platform Technology for HIV Cure

Gilead Sciences and Gritstone Announce Collaboration Utilizing Gritstone’s Vaccine Platform Technology for HIV Cure

Gilead Sciences and Gritstone Announce Collaboration Utilizing Gritstone’s Vaccine Platform Technology for HIV Cure

Gilead Sciences and Gritstone Announce Collaboration Utilizing Gritstone’s Vaccine Platform Technology for HIV Cure

FOSTER CITY, Calif. & EMERYVILLE, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company ...

Johnson & Johnson Announces New Public-Private Partnership to Support First Phase 3 Efficacy Study of Janssen’s Investigational Prophylactic HIV Vaccine

Johnson & Johnson Announces New Public-Private Partnership to Support First Phase 3 Efficacy Study of Janssen’s Investigational Prophylactic HIV Vaccine

National Institutes of Health (NIH), HIV Vaccine Trials Network (HVTN) and U.S. Army Medical Research and Development Command (USAMRDC) join forces with Johnson & Johnson to advance global ...

Moderna Announces First Participants in Each Age Cohort Dosed in Phase 2 Study of mRNA Vaccine (mRNA-1273) Against Novel Coronavirus

Moderna Announces First Participants in Each Age Cohort Dosed in Phase 2 Study of mRNA Vaccine (mRNA-1273) Against Novel Coronavirus

Phase 2 study expected to enroll 600 participants Finalizing protocol for Phase 3 study, expected to begin in July 2020 CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 29, 2020-- Moderna, Inc. , ...

GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update

GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update

The Underlying Value of GeoVax, and the Promise of the Technology...A Comprehensive Review of GeoVax's Various Development Programs ATLANTA, GA, November 7, 2019 – GeoVax Labs, Inc. (OTCQB: ...

Lessons from AIDS for the COVID-19 Pandemic

Lessons from AIDS for the COVID-19 Pandemic

We can learn from parallels between the coronavirus and HIV crises

HIV prevention is making progress. And a breakthrough vaccine appears within reach

HIV prevention is making progress. And a breakthrough vaccine appears within reach

A spate of large-scale clinical trials has scientists hopeful about a vaccine to prevent HIV.

HIV vaccine in 2021? Leading experts 'optimistic' about ongoing trials

HIV vaccine in 2021? Leading experts 'optimistic' about ongoing trials

Drs. Susan Buchbinder and Anthony Fauci, two of the world’s leading HIV experts, say three ongoing HIV vaccine trials are reason to be hopeful.

Scholar Rock Appoints Tony Kingsley as President and CEO

Scholar Rock Appoints Tony Kingsley as President and CEO

- Nagesh Mahanthappa , Ph.D., MBA, company’s founding chief executive, passes the baton after leading company since 2012 - Tony Kingsley , a proven leader with a successful track record of ...

Could certain COVID-19 vaccines leave people more vulnerable to the AIDS virus?

Could certain COVID-19 vaccines leave people more vulnerable to the AIDS virus?

Cold-causing adenovirus used in four experimental COVID-19 vaccines increased risk of HIV infection when used in AIDS vaccine trials